Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Neurotrope gets more bryostatin IP from Stanford University

Executive Summary

Stanford University licensed therapeutics and diagnostics start-up Neurotrope Inc. exclusive global rights to manufacture and market bryostatin analogs, or bryologs, for neurodegenerative diseases (including Fragile X, traumatic brain injury, and Alzheimer’s), lysosomal storage disorders, stroke, and cardioprotection. The transaction includes three issued US patents, one pending US patent, and related technology.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Technologies
      • Molecular Diversity
        • Natural Products
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Manufacturing or Supply
    • R&D and Marketing (Licensing)

Related Companies